What are the AUA treatment guidelines for asymptomatic non-metastatic castration-resistant prostate cancer (CRPC)?

Updated: Jul 31, 2017
  • Author: Bagi RP Jana, MD; more...
  • Print


Recommendations are as follows:

  • Observation with continued ADT

  • First-generation antiandrogens (flutamide, bicalutamide, and nilutamide) or first-generation androgen-synthesis inhibitors (ketoconazole plus steroid) to patients unwilling to accept observation.

  • Systemic chemotherapy or immunotherapy should not be offered to patients with non-metastatic CRPC outside the context of a clinical trial

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!